CEOInterviews.AI
Start App
Try: AI strategy tariffs earnings guidance layoffs interest rates growth

Pablo Legorreta

Founder, Chairman and Chief Executive Officer, Royalty Pharma plc

Search every verified Pablo Legorreta interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Pablo Legorreta, founder, chairman, and CEO of Royalty Pharma, discussed the company's performance and outlook during its Q2 2024 earnings call on August 8, 2024. He noted the company raised its full-year guidance by over $100 million, citing strong performance and opportunities in high-quality assets. Legorreta stated that Royalty Pharma's stock price at the time reflected only the value of its existing portfolio, and he expressed confidence in the team's ability to deploy capital and generate compounding growth. He also mentioned that the company had repurchased $115 million of its shares from the second quarter through the date of the call. In earlier appearances, Legorreta has described Royalty Pharma's business model as investing in royalty interests in late-stage biomedical products rather than conducting traditional drug development. He has characterized the life sciences sector as a large and growing industry, citing figures such as $300 billion invested annually in medical research worldwide. He has also discussed the company's role in funding innovation through collaborations with academic institutions and biotechnology companies, and has emphasized the scale of Royalty Pharma relative to competitors in the royalty acquisition space.

Recent appearances

  • $RPRX Royalty Pharma Q2 2024 Earnings Conference Call

    August 15, 2024 · 📺 EARNMOAR

    08/08/2024 Q&A: 25:16 Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage prod…

    Watch on YouTube ↗

  • April 2021 Entrepreneurs Edge Program

    April 21, 2021 · 📺 StonyBrookCOB

    Featuring Pablo Legorreta, Founder and Chief Executive Officer of Royalty Pharma, the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, interviewed by Joe Campolo, '94, Managing Partner at Campolo, Middleton & McCormick, LLP.

    Watch on YouTube ↗

  • #SecretsSelfmadeBillionaire 0786 Pablo Legorreta Royalty Pharma & Golden Age of BioTech 9 Lessons

    June 24, 2020 · 📺 #SecretsSelfmadeBillionaires by Paul Chan

    Pablo Legorreta We are now in the Golden Age of BioTech. How not to do what conventional drug development do. Make it a Win-Win Situation. On the Securitization of Risks. Avoid Hit or Miss. Involve in Late Stage Clinical Trials. US is still the Best Place in the world for BioTech Investing. Smaller Clinical Trials is the Future. How Big is the BioTech Pie?

    Watch on YouTube ↗

  • Royalty Pharma CEO on taking the company public

    June 16, 2020 · 📺 CNBC Television

    Pablo Legorreta, CEO and founder of Royalty Pharma, joins "Squawk on the Street" to discuss the company’s public debut in what will be 2020’s largest IPO to-date and the second largest Pharma IPO on record. For access to live and exclusive video from CNBC subscribe to CNBC PRO: https://cnb.cx/2JdMwO7 » Subscribe to CNBC TV: https://cnb.cx/SubscribeCNBCtelevision » Subscribe to CNBC: https://cnb.cx/SubscribeCNBC » Subscribe to CNBC Classic: https://cnb.cx/SubscribeCNBCclassic Turn to CNBC TV for the latest stock market news and analysis. From market futures to live price updates CNBC is…

    Watch on YouTube ↗

  • Pablo Legorreta Founder and Chief Executive Officer, Royalty Pharma

    January 21, 2013 · 📺 americanmontage

    Mr. Legorreta founded Royalty Pharma in 1996, after creating and managing two "proof of principle" investment vehicles in 1993 and 1994 that invested in royalty interests in two leading biotechnology products. Since its inception in 1996, Royalty Pharma has expanded the traditional parameters that define a pharmaceutical company. By focusing on intellectual property - the key to premium pricing and profits in the pharmaceutical industry - Royalty Pharma has become the global leader in the acquisition of royalty interests. Royalty Pharma has assembled a well-diversified and well-balanced portfo…

    Watch on YouTube ↗

The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →